• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

    3/21/24 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTMX alert in real time by email

    SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors.

    "We are excited to welcome Zhen to our board," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "With his extensive experience and accomplishments in oncology, Zhen brings expertise that will help shape strategy across our multi-modality PROBODY® therapeutic pipeline as well as CytomX's continued growth and leadership in the field of conditionally activated, localized biologics. Zhen's patient-focused leadership and commitment to making a meaningful difference for cancer patients strongly aligns to our vision of transforming lives with safer, more effective therapies."

    Dr. Su is an accomplished physician executive with nearly three decades of experience leading oncology research and development and commercial organizations. Dr. Su is currently chief executive officer of Marengo Therapeutics and a member of its Board of Directors. During his tenure at Marengo, Dr. Su has led the teams progressing the company's lead asset into clinical trials, grown its leading-edge pipeline, and brokered a $1.6 billion partnership with Ipsen.

    Prior to joining Marengo, Dr. Su was senior vice president and global head of the oncology business franchise for Merck KGaA. Before that, he was the chief medical officer at EMD Serono. Dr. Su also held increasing leadership roles at Sanofi and GlaxoSmithKline. Before joining the industry, he served on the faculty of Duke University Medical School, where he led early oncology clinical studies focused on mRNA-based and cell-based immunotherapy, and at University of Florida, where he was the director of the cell and gene therapy program. Dr. Su also serves on the board of directors of Karyopharm Therapeutics and as the funding chairperson for the biotech committee of the Society for Immunotherapy of Cancer (SITC).

    "I am excited for the opportunity to join CytomX's board as the company continues to advance its pipeline and work to address large oncology markets with significant unmet need. CytomX's proprietary PROBODY® technology is a highly anticipated innovation to the field of oncology, where many potent treatment modalities are constrained by the limited therapeutic index. The CytomX current clinical stage pipeline holds tremendous promise for patients, and I look forward to collaborating with the board and the executive team to advance innovative therapies to cancer patients," said Dr. Su.

    Dr. Su received his M.D. from Technical University of Dresden in Germany and his M.B.A. from the University of Toronto, Rotman School of Management.

    About CytomX Therapeutics

    CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX's vision is to create safer, more effective therapies for the treatment of cancer. CytomX's robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates ("ADCs"), T-cell engagers, and immune modulators such as cytokines. CytomX's clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule, EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CX-801 is an interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

    CytomX Therapeutics Forward-Looking Statements

    This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements, including those related to the future potential of partnerships or collaboration agreements. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety and efficacy or progress of CytomX's or any of its collaborative partners' product candidates, including CX-2051, CX-801, and CX-904, the potential benefits or applications of CytomX's PROBODY® therapeutic platform, CytomX's or its collaborative partners' ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing and planned clinical trials of CX-904, and the timing of the commencement of clinical trials or initial and ongoing data availability for CX-801 and CX-2051, and other development milestones. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the unproven nature of CytomX's novel PROBODY® therapeutic technology; CytomX's clinical trial product candidates are in the initial stages of clinical development and its other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties, including the possibility that the results of preclinical research and early clinical trials may not be predictive of future results; the possibility that CytomX's clinical trials will not be successful; the possibility that current preclinical research may not result in additional product candidates; CytomX's dependence on the success of CX-904, CX-801, and CX-2051; CytomX's reliance on third parties for the manufacture of the Company's product candidates; possible regulatory developments in the United States and foreign countries; and the risk that we may incur higher costs than expected for research and development or unexpected costs and expenses. Additional applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX's Annual Report on Form 10-K filed with the SEC on March 11, 2024. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

    PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc.

    Investor Contact:

    Chris Ogden

    SVP, Finance and Accounting

    [email protected]

    Investor and Media Contact:

    Stern Investor Relations

    Stephanie Ascher

    [email protected]



    Primary Logo

    Get the next $CTMX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTMX

    DatePrice TargetRatingAnalyst
    7/31/2025$7.00Outperform
    Oppenheimer
    5/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    4/14/2025$3.25 → $2.50Overweight
    Piper Sandler
    5/28/2024$2.25 → $3.50Neutral → Overweight
    Piper Sandler
    5/9/2024$8.00Neutral → Outperform
    Wedbush
    5/6/2024$2.50 → $8.00Hold → Buy
    Jefferies
    4/22/2024Underweight → Neutral
    JP Morgan
    11/14/2022$3.00 → $2.60Outperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $CTMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on CytomX Therapeutics with a new price target

    Oppenheimer initiated coverage of CytomX Therapeutics with a rating of Outperform and set a new price target of $7.00

    7/31/25 7:18:02 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded CytomX Therapeutics from Neutral to Buy and set a new price target of $5.00

    5/15/25 8:05:24 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler resumed coverage on CytomX Therapeutics with a new price target

    Piper Sandler resumed coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $2.50 from $3.25 previously

    4/14/25 8:16:21 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    SEC Filings

    View All

    SEC Form EFFECT filed by CytomX Therapeutics Inc.

    EFFECT - CytomX Therapeutics, Inc. (0001501989) (Filer)

    8/19/25 12:15:20 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by CytomX Therapeutics Inc.

    SCHEDULE 13G - CytomX Therapeutics, Inc. (0001501989) (Subject)

    8/14/25 6:07:11 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.

    SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    8/14/25 4:15:07 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Ogden Christopher sold $33,381 worth of shares (12,255 units at $2.72) and converted options into 37,500 shares, increasing direct ownership by 13% to 226,271 units (SEC Form 4)

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    6/17/25 4:11:18 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Scientific Officer Belvin Marcia converted options into 37,500 shares and sold $37,334 worth of shares (13,884 units at $2.69), increasing direct ownership by 9% to 272,252 units (SEC Form 4)

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    6/17/25 4:10:00 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Mccarthy Sean A. converted options into 150,000 shares and sold $149,264 worth of shares (55,511 units at $2.69), increasing direct ownership by 9% to 1,089,684 units (SEC Form 4)

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    6/17/25 4:09:02 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study

    - The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company's goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all expansion doses - SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today provided an update on the CX-2051 Phase 1 study to address certain recent social media posts.   "Since our initial data disclosure in May 2025, Phase 1 enrollment has been rapid and is substantially complete. We are on track to pr

    8/13/25 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

    - May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track for data update in Q1 2026. Phase 2 study initiation in CRC anticipated 1H 2026 - - Combination dose escalation initiated of CX-801 masked interferon alpha-2b with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma - - Completed $100 million underwritten offering of common stock - - Company to host conference call today at 5 p.m. EST / 2 p.m. PST - SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader

    8/7/25 4:10:00 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025

    SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter financial results on Thursday, August 7, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minu

    7/31/25 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:26:32 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:00:06 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 3:03:21 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Financials

    Live finance-specific insights

    View All

    CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

    - May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track for data update in Q1 2026. Phase 2 study initiation in CRC anticipated 1H 2026 - - Combination dose escalation initiated of CX-801 masked interferon alpha-2b with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma - - Completed $100 million underwritten offering of common stock - - Company to host conference call today at 5 p.m. EST / 2 p.m. PST - SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader

    8/7/25 4:10:00 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025

    SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter financial results on Thursday, August 7, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minu

    7/31/25 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

    - Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) - - Initiated CX-2051 Phase 1 dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses. Additional CX-2051 Phase 1 data update expected by Q1 2026 - - Planning CX-2051 Phase 2 study initiation in 1H 2026 - - CX-801 (PROBODY® Interferon alpha-2b) Phase 1a translational data in advanced melanoma expected in 2H 2025 - - Company to host conference call today at 8 a.m. EST / 5 a.m. PST - SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics,

    5/12/25 6:15:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Leadership Updates

    Live Leadership Updates

    View All

    CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

    SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors. "We are excited to welcome Zhen to our board," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "With his extensive experience and accomplishments in oncology, Zhen brings expertise that will help shape strategy across our multi-modality PROBODY® therapeutic pipeline as well as CytomX's continued growth an

    3/21/24 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO). In this role, Dr. Chu will oversee clinical development of the Company's diversified portfolio of Probody® therapeutic candidates. "Wayne brings to CytomX substantial experience in clinical development strategy in the oncology space," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. "His drug development experiences have contributed to multiple approvals and span therapeutic modalitie

    7/17/23 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

    SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company's next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022. Dr. Scarlett has served as a member of the CytomX Therapeutics board since June 2016, and is currently chair of the Compensation Committee and a member of the Audit Committee. He also serves as chairman and chief executive officer of Geron Corporation. "I would like to express my s

    4/14/22 4:15:00 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care